BerandaMVIR • STO
add
Medivir AB
Tutup sebelumnya
kr 2,70
Rentang hari
kr 2,66 - kr 2,74
Rentang tahun
kr 2,33 - kr 4,71
Kapitalisasi pasar
303,97Â jt SEK
Volume Rata-Rata
89,72Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
STO
Berita pasar
MSN
1 hari yang lalu
Wall Street Reli: Dow, S&P 500 dan Nasdaq Menguat, Ditopang Data Aktivitas
Bisnis
3,22%
0,35%
0,97%
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (SEK) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 900,00Â rb | 12,50% |
Biaya operasional | 7,30Â jt | 5,80% |
Laba bersih | -34,60Â jt | -46,61% |
Margin laba bersih | -3,84Â rb | -30,32% |
Penghasilan per saham | -0,30 | 28,57% |
EBITDA | -35,30Â jt | -50,21% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (SEK) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 92,50Â jt | 51,39% |
Total aset | 204,20Â jt | 15,96% |
Total liabilitas | 62,40Â jt | 20,93% |
Total ekuitas | 141,80 jt | — |
Saham yang beredar | 112,17 jt | — |
Harga terhadap nilai buku | 2,14 | — |
Tingkat pengembalian aset | -40,60% | — |
Tingkat pengembalian modal | -53,35% | — |
Arus Kas
Perubahan kas bersih
| (SEK) | Sep 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -34,60Â jt | -46,61% |
Kas dari operasi | -33,40Â jt | -59,05% |
Kas dari investasi | — | — |
Kas dari pembiayaan | -600,00Â rb | 0,00% |
Perubahan kas bersih | -34,10Â jt | -57,14% |
Arus kas bebas | -21,80Â jt | -71,32% |
Tentang
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Didirikan
1988
Situs
Karyawan
10
